Official Title Quantifying Musculoskeletal Adaptations to Manual Wheelchair Use Across the Lifespan

Purpose

Manual wheelchair use places high physical demands on the arms and shoulders, which can lead to pain and injury, especially with aging. This study aims to understand how wheelchair use affects shoulder anatomy and movement to improve prevention, early detection, and treatment of upper extremity pain and injury in manual wheelchair users.

Participation includes two in-person research sessions, each lasting about 60 minutes, conducted at the Martha Morehouse Medical Pavilion:

• MRI session to examine shoulder anatomy (no radiation involved)
• Movement analysis session to assess muscle activity and arm function during everyday tasks such as wheelchair propulsion and reaching

Sessions may be completed on the same day or on different days within one week.

Total study participation is approximately 2 hours.

Could this study be right for you?

• Adults (>18 years old) who are primary manual wheelchair users
• Must be able to safely participate in MRI and movement analysis
• Individuals who are pregnant or have MRI-incompatible metal implants are not eligible

Age Range

18 - 110 years

Contact Information

Martha Morehouse Medical Plaza

Wheelchair User Shoulder Health (WUSH) Study Team

WUSHStudy@osumc.edu

Official Title CP-MOVES: Complex rehabilitation technology enabled Physical activity for children with Motor delays Via telehealth in natural Environments

Purpose

This study will examine physical activity, sleep, and quality of life in children with severe motor delays and their parents before and after an 8-week intervention using adaptive standers.

Parents with a child with severe motor delay will enroll with their child (up to 1 parent per child). Both parent and child will participate in one telehealth-supervised session per week and two unsupervised sessions per week. Both parent and child will wear activity trackers on the wrists and waist for 1 week before and 1 week after treatment in order to measure physical activity and sleep. Parents will also complete surveys on quality of life before and after treatment. 

Could this study be right for you?

• Medical diagnosis causing motor delay 
• Unable to stand independently 
• A parent or primary caregiver able to enroll as a participant in the study 
• Internet or cellular service to join telehealth sessions  
• Live within 100 miles of Ohio State University or willing to travel to the lab for one visit 

Age Range

1 - 6 years

Contact Information

Martha Morehouse Pavilion and Remote

Petra Sternberg

Petra.Sternberg@osumc.edu

614-572-5446

Official Title Resource Mapping for Families of Children with Brain Injury

Purpose

The purpose of this study is to assess the family needs of children with a brain injury. We want to explore your experiences getting care, the barriers, and facilitators your family has faced in navigating and accessing services after hospital discharge, and your ongoing unmet needs.

Could this study be right for you?

• You are a primary care giver of a child that sustained a brain injury

• Your child was hospitalized for an overnight stay as a result of their brain injury
• Your child was 18 or younger when their brain injury occurred
• You speak English 

Age Range

19 years and up

Contact Information

Virtual

Archana Kaur

Archana.Kaur@nationwidechildrens.org

Official Title OASIS - Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

Purpose

This study will look at whether suvorexant can help treat alcohol use disorder, how it works, and who it works best for. Suvorexant is a medicine that blocks certain brain signals linked to wakefulness.

 

Your total participation time in this study will be approximately 9 weeks.

Could this study be right for you?

Inclusion Criteria: 

1. Age 18-65
2. Participant is able to give informed consent 
3. Engage in heavy alcohol use defined as drinking ≥14 standard drinks per week if male and ≥7 standard drinks per week if female. 

General - Exclusion Criteria

1. Clinically significant medical or neurological condition (e.g., liver disease, narcolepsy, complex sleep behaviors, severe hepatic impairment, COPD, severe obstructive sleep apnea) 
2. Current or past DSM-5 diagnosis of mania, schizophrenia, psychosis 
3. Past suicide attempt within 3 years or presence of moderate suicidal ideation
4. Engage in night-shift work 

 

 

Age Range

18 - 65 years

Contact Information

Institute for Behavior, Brain, and Immunology at the Ohio State University Wexner Medical Center

Annabel Fuller

annabel.fuller@osumc.edu

6143663523

Official Title Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)

Purpose

The purpose of this study is to evaluate the safety and tolerability of dasatinib and quercetin (D+Q) and efficacy of this regimen in improving physical function outcomes in people with HIV (PWH) who are frail or prefrail.

Could this study be right for you?

• People living with HIV ≥50 years diagnosed with HIV 10 or more years ago
• Currently on combination antiretroviral therapy
• Currently virologically suppressed
• Must meet FFP criteria & have 4-meter gait speed in the range of .5-1.2 m/sec

Age Range

50 years and up

Contact Information

McCampbell Hall

Jessica Marburger

Jessica.Marburger@osumc.edu

Official Title A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)

Purpose

This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.

People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.

Researchers hope this treatment will:

• Help the body keep making some of its own insulin

• Reduce the amount of insulin people need to take

• Improve blood sugar control

• Lower the risk of very low blood sugar levels

The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.

Could this study be right for you?

• Must be diagnosed with Type 1 Diabetes in the past 2 months
• Must have had a positive test for at least one Type 1 Diabetes antibody
• For female participants of childbearing potential - must use a contraception method (or abstinence) 

Age Range

18 - 25 years

Contact Information

Ohio State University Wexner Medical Center

Lindsey Aldrich

lindsey.aldrich@osumc.edu

614-814-0772

Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

Purpose

This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.

People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 4 or more observable focal seizures per month
2. Taking at least 1 and up to 3 anti-seizure medications
3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months
4. Between the ages of 18 to 75

Age Range

18 - 75 years

Contact Information

300 W 10th Ave, Columbus, OH, 43210

Emily Huber

emily.huber@osumc.edu

614-814-1120

Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Purpose

In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use.  People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 3 PGTCS in an 8-week period
2. Have tried at least 2 anti-seizure medications without success
3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
4. 18 years old and up

Age Range

18 years and up

Contact Information

300 W 10th Ave, Columbus, OH, 43210

Emily Huber

emily.huber@osumc.edu

614-814-1120

Official Title The Foods and Oils to Repair Correct and Enhance Strength (FORCES) Study: Determining the effect of dietary oils on muscle function, strength and mass

Purpose

The purpose of the FORCES Study is to determine how dietary oils effect muscle function, strength and mass in older adults who feel their muscle function and strength has declined with age.

During this 27-week study participants will

•  Consume ~2.5 tsp of oil each day through foods

• Complete muscle function and strength testing

• Have their blood drawn

• Have their body weight and composition measured

• Have an MRI scan of your legs, if able

• Fill out questionnaires

• Collect a small amount of muscle tissue from the leg (muscle biopsy

Could this study be right for you?

Feel your muscle function, strength or mass as decreased with age

Do NOT have food allergies 

Are not taking any weight loss medications or following a weight loss program

Age Range

65 - 80 years

Contact Information

The Ohio State University Columbus Campus

Rachel Cole

belurylabstudies@osu.edu

614-247-8235

Official Title Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to Immunotherapy

Purpose

This study will look at if a ketogenic diet (KD) can help treatment work better in patients with metastatic melanoma or metastatic kidney cancer. People who take part in the study will be randomly assigned to either continue eating their usual diet or trying the KD diet for 24 weeks. Participants will have blood and stool samples collected during the study. They will also test their sugar by doing daily glucose fingers sticks. Participants may be paid up to $200 for taking part in the study.

Could this study be right for you?

1. Patients with metastatic melanoma receiving first-line treatment with immunotherapy or Patients with metastatic renal cell cancer receiving first line treatment with immunotherapy.
2. Willing to give three stool samples
3. Willing to participate in a ketogenic diet (KD)

Age Range

18 years and up

Contact Information

The Ohio State University

Helena Gastier

_JOC-NTresearch_@osumc.edu

614-257-3434

Official Title The Knowledge and Perceptions of Gen Zs Regarding the Dietary Guidelines for Americans

Purpose

1. Use ideas from Social Cognitive Theory to describe Gen Zs regarding the Dietary Guidelines for Americans (DGA) 2020 to 2025
2. Explain what Gen Z knows and believes regarding the MyPlate recommendations for healthy eating related to:

• Filling half their plate with fruit and vegetables
• Filling one-quarter of their plate with lean protein, and varying the sources of protein
• Filling one-quarter of their plate with grains, making half of the grains whole grains

3. To describe the associations between demographic variables (ethnicity, education, household income, and home environment) and Gen Zs perceptions and knowledge of the DGA

Could this study be right for you?

18 to 28 years old

Live in the US

English speaker

Have access to a device that supports Zoom

Age Range

18 - 28 years

Contact Information

United States

Livia Schorn or Rhea Umrani

umrani.2@buckeyemail.osu.edu; schorn.5@buckeyemail.osu.edu

614-814-0866

Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Contact Information

Columbus, OH

Zachary Dohar

Zachary.Dohar@osumc.edu

614-814-0377